Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Hu, Shuiying

Ohio State University
United States

Targeting neuronal transport to ameliorate vincristine neurotoxicity 5R01CA272254-03 Rachel Altshuler, Ph.D.
Hu, Jim

Weill Medical Coll Of Cornell Univ
United States

Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL) 5R01CA259173-04 Marjorie Perloff, M.D.
Hu, Jim

Weill Medical Coll Of Cornell Univ
United States

Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL) 5R01CA259173-04 Marjorie Perloff, M.D.
Huang, Ying

Fred Hutchinson Cancer Center
United States

Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies 5R01CA277133-03 Matthew Young, Ph.D.
Huang, Ying

Western University Of Health Sciences
United States

Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilol 5R01CA269653-04 Anda Vlad, M.D., Ph.D.
Huang, Yijian

Emory University
United States

Analytic diagnosis methods for disease ruling 5R01CA283687-02 Guillermo Marquez, Ph.D.
Huberty, Jennifer Lynne

University Of Texas Hlth Science Center
United States

Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patients 5R01CA262041-05 Marjorie Perloff, M.D.
Huberty, Jennifer Lynne

University Of Texas Hlth Science Center
United States

Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patients 5R01CA262041-05 Marjorie Perloff, M.D.
Huh, Warner King

University Of Alabama At Birmingham
United States

Misoprostol to Optimize Prevention of Cancer of the Cervix: A Randomized Trial (MISOPCx Project) 3R01CA279021-02S1 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Hui, David

University Of Tx Md Anderson Can Ctr
United States

Strategies for Personalizing Oxygen and support Therapies for dyspnea in Oncology 5R01CA288515-02 Brennan Streck, Ph.D., RN, M.P.H.
Hui, David

University Of Tx Md Anderson Can Ctr
United States

Strategies for Personalizing Oxygen and support Therapies for dyspnea in Oncology 5R01CA288515-02 Brennan Streck, Ph.D., RN, M.P.H.
Hundley, William Gregory

Wake Forest University Health Sciences
United States

Improving Exercise Capacity with a Tailored Physical Activity Intervention in Lymphoma Patients Undergoing Treatment 5R33CA226960-05 Eileen Dimond, R.N., M.S.
Hundley, William Gregory

Wake Forest University Health Sciences
United States

Improving Exercise Capacity with a Tailored Physical Activity Intervention in Lymphoma Patients Undergoing Treatment 5R33CA226960-05 Eileen Dimond, R.N., M.S.
Hundley, William Gregory

Wake Forest University Health Sciences
United States

Improving Exercise Capacity with a Tailored Physical Activity Intervention in Lymphoma Patients Undergoing Treatment 5R33CA226960-05 Eileen Dimond, R.N., M.S.
Hur, Chin

Columbia University Health Sciences
United States

Optimal Colorectal Cancer Surveillance Strategy for Lynch Syndrome by Genotype 3R01CA257333-05S1 Matthew Young, Ph.D.